What Is CAR T-Cell Therapy?
CAR T-cell therapy is a specialized, genetically engineered subtype of adoptive cell therapy (ACT). In CAR T-cell therapy, the person's immune cells, usually T-cells, are collected and modified in a lab to add a synthetic chimeric antigen receptor (CAR) so they can specifically hunt down and destroy cancer cells. Afterward, the newly manufactured T-cells are placed in your blood to find and fight the myeloma.
A few potential benefits of CAR T-cell therapy may include:
- Short treatment period: The treatment is administered in a single infusion, which usually results in a shorter treatment duration.
- Longer remissions: This type of therapy may help many people living with myeloma achieve longer remissions — the partial or complete disappearance of myeloma symptoms.
- Ongoing therapy benefits: Because this therapy creates cells that live in the body long-term, CAR T-cells may recognize and attack myeloma cells over time.
- Reduced need for other treatments: In specific cases, therapy may reduce the need for stem cell transplants.
How Long Does CAR T-Cell Therapy Take?
The process takes several months from collecting the T-cells to recovering post-infusion. This immunotherapy has three distinct phases:
Collection
This phase involves gathering your body's T-cells through leukapheresis. Blood is removed from your body using an IV line, and an apheresis machine extracts the white blood cells. Another IV line returns your blood to your body. This process can take around three to six hours, and T-cells may be collected across multiple sessions.
Manufacturing
The removed white blood cells are frozen and shipped to a cell therapy lab. Then, technicians genetically alter the cells so they develop CAR. Growing and multiplying CAR T-cells in the lab can be a multi-week process.
Infusion
When the cells have multiplied to a sufficient amount, they'll be returned to your blood via infusion. This phase may last around an hour.
Recovery Arc and Remission
This type of therapy often requires a hospital stay after administration, which may last a couple of weeks, so healthcare staff can monitor you for a reaction. Though it can effectively treat multiple myeloma, there are CAR T-cell side effects to be aware of, such as:
- Cytokine release syndrome (CRS): Multiplying CAR T-cells can release many cytokines, chemicals in the blood that can cause symptoms like fever, nausea, and lightheadedness.
- Immune effector cell-associated neurotoxicity syndrome (ICANS): This therapy can affect your nervous system and cause ICANS, resulting in side effects like confusion, tremors, and headaches.
Your healthcare team will monitor your reaction to the treatment, grading the side effects and using targeted medications to manage and reverse these symptoms.
After discharge, you will need to attend regular check-ins at the hospital, which may require you to stay close to the treatment center. Once you return home, you and your healthcare team will need to create a plan to rebuild strength, manage cytopenia (low blood count), and monitor for deep remissions.
Emerging CAR T-Cell Therapies
The Food and Drug Administration (FDA) has approved some products, including:
- ABECMA® (idecabtagene vicleucel, or ide-cel): This therapy treats people living with relapsed or nonresponsive, also called refractory, multiple myeloma who have been exposed to the three main classes of treatment.
- CARVYKTI® (ciltacabtagene autoleucel, or cilta-cel): This is another treatment for relapsed multiple myeloma, designed for people who have had therapy at least once before.
Currently, researchers are developing other CAR T-cell treatments in clinical trials. However, the therapy is not widely available, and not all individuals living with myeloma can participate. Only those who have relapsed or refractory disease may be eligible.
Learn More About CAR T-Cell for Myeloma
The International Myeloma Foundation (IMF) is dedicated to improving the quality of life for individuals living with myeloma, which includes informing you and your loved ones about CAR T-cell therapy for multiple myeloma. With over 50 cure-focused research projects and a library of online resources, we prioritize people while working toward finding a cure. Reach out to an IMF InfoLine Coordinator for resources and support by calling 1-800-452-CURE (2873) today.
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape.
Additionally, the content on this page is medically reviewed by myeloma physicians and healthcare professionals.
Last Medical Content Review: May 8, 2024




